Our colleague, MUDr. Mgr. Sandra Charvátová, Ph.D., has been awarded a G-Rex grant to support the development of new cancer immunotherapies. Thanks to this grant, we will be able to use innovative technology for the efficient production of cells that can help treat cancer through personalized immunotherapy. This grant will accelerate our research and bring this promising treatment closer to patients
At the beginning of this year, the University Hospital Ostrava was awarded a $75,000 G-Rex® Grant, initiative by ScaleReady, Wilson Wolf Manufacturing, Bio-Techne, and CellReady, to support the early-stage development of CAR-T and CAR-NK cell therapies targeting hematologic malignancies.
The grant will accelerate the implementation of G-Rex® cell expansion technology within the hospital’s translational research pipeline. The project, led by the Department of Hematooncology, focuses on optimizing upstream cell manufacturing protocols, including activation, transduction, and expansion, for T and NK cell therapies. These efforts will contribute to the establishment of a standardized, scalable platform for future clinical-grade production.
This initiative forms a cornerstone of the department’s long-term strategy to build institutional capacity for advanced therapy medicinal products (ATMPs). A specialized bioincubator for cell therapy manufacturing is planned, and this grant-supported phase provides the scientific and process development framework required for regulatory and clinical readiness.
The G-Rex® platform, widely adopted by leading cell therapy centers worldwide, enables high-density, high-viability expansion of immune effector cells while simplifying the manufacturing workflow. Its integration in Ostrava reinforces the hospital’s commitment to innovation and positions the region as a contributor to the rapidly evolving field of personalized cancer immunotherapy.
For more information about the G-Rex® Grant program, visit the ScaleReady website: https://www.scaleready.com/g-rex-grant-program.